Which diabetes pill combo works best? new study pits three options Head-to-Head

NCT ID NCT06759922

Completed Disease control Sponsor: Bahria University Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This completed study tested different combinations of diabetes drugs (glimepiride, empagliflozin, or sitagliptin) taken with metformin in 172 adults newly diagnosed with type 2 diabetes. Participants were split into four groups and took their assigned pills once daily for 90 days. Researchers measured blood sugar control (HbA1c), weight, cholesterol, and side effects to see which combination worked best and was safest.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Metformin combined with glimepiride, empagliflozin, or sitagliptin
What this could lead to: If successful, this could help doctors choose the most effective and safe two- or three-drug combination for managing blood sugar in newly diagnosed type 2 diabetes patients.
What could go wrong: This is a small, completed Phase 4 trial, so results may not apply to all patients. Side effects like diarrhea, weight gain, or urinary infections are possible with these drugs.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for TYPE 2 DIABETES MELLITUS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

type 2 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

TYPE 2 DIABETES MELLITUS

Contacts and locations

Locations

National Medical Center

Karachi, Sindh, 75500, Pakistan

More trials for these conditions

Other studies related to the condition(s) this trial covers.